Email discussing FDA approval of pricey cholesterol‑lowering shot (Praluent)
The passage merely references a publicly announced FDA drug approval and a casual email exchange. It contains no new allegations, financial flows, or links to high‑level officials, and offers no actio FDA approved Praluent, a costly injectable cholesterol drug. Email sender Jeffrey E. confirms the drug requires a shot and lacks long‑term safety data. Forbes article by Matthew Herper cited as sourc
Summary
The passage merely references a publicly announced FDA drug approval and a casual email exchange. It contains no new allegations, financial flows, or links to high‑level officials, and offers no actio FDA approved Praluent, a costly injectable cholesterol drug. Email sender Jeffrey E. confirms the drug requires a shot and lacks long‑term safety data. Forbes article by Matthew Herper cited as sourc
Tags
Ask AI About This Document
Extracted Text (OCR)
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
jeevacation@gmail.comRelated Documents (6)
EFTA02457370
EFTA Document EFTA02190107
EFTA Document EFTA01819963
EFTA01929831
EFTA Document EFTA01742298
EFTA02569122
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.